Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial"

Circulation. 2021 Mar 30;143(13):e797-e798. doi: 10.1161/CIRCULATIONAHA.120.051945. Epub 2021 Mar 29.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Humans
  • Prasugrel Hydrochloride / adverse effects
  • ST Elevation Myocardial Infarction* / diagnosis
  • ST Elevation Myocardial Infarction* / drug therapy
  • Tirofiban

Substances

  • Adenosine Monophosphate
  • cangrelor
  • Prasugrel Hydrochloride
  • Tirofiban